In this regard, ex vivo leukemia drug-sensitivity profiling identified that 44.4% of childhood T-ALL samples and 16.7% of adult T-ALL samples as being sensitive to dasatinib through the inhibition of preTCR-LCK signaling [106]. Here, LCK is linked to acute lymphoblastic leukemia.